Abstract:By taking advantage of the pH-sensitive drug release property of graphene oxide (GO) after intracellular uptake, we prepared folic acid (FA)-conjugated GO (GOFA) for targeted delivery of the chemotherapeutic drug doxorubicin (DOX). GOFA-DOX was further encapsulated in an injectable in-situ forming thermo-sensitive hyaluronic acid-chitosan-g-poly(N-isopropylacrylamide) (HACPN) hydrogel for intratumoral delivery of DOX. As the degradation time of HACPN could be extended up to 3 weeks, intratumoral delivery of GOFA-DOX/HACPN could provide controlled and targeted delivery of DOX through slow degradation HACPN and subsequent cellular uptake of released GOFA-DOX by tumor cells through interactions of GOFA with folate receptors on the tumor cell's surface. GOFA nano-carrier and HACPN hydrogel were first characterized for the physico-chemical properties. The drug loading experiments indicated the best preparation condition of GOFA-DOX was by reacting 0.1 mg GOFA with 2 mg DOX. GOFA-DOX showed pH-responsive drug release with ~5 times more DOX released at pH 5.5 than at pH 7.4 while only limited DOX was released from GOFA-DOX/HACPN at pH 7.4. Intracellular uptake of GOFA by endocytosis and release of DOX from GOFA-DOX in vitro could be confirmed from transmission electron microscopic and confocal laser scanning microscopic analysis with MCF-7 breast cancer cells. The targeting effect of FA was revealed when intracellular uptake of GOFA was blocked by excess FA. This resulted in enhanced in vitro cytotoxicity as revealed from the lower half maximal inhibitory concentration (IC50) value of GOFA-DOX (7.3 μg/mL) compared with that of DOX (32.5 μg/mL) and GO-DOX (10 μg/mL). The flow cytometry analysis indicated higher apoptosis rates for cells treated with GOFA-DOX (30%) compared with DOX (8%) and GO-DOX (11%). Animal studies were carried out with subcutaneously implanted MCF-7 cells in BALB/c nude mice and subject to intratumoral administration of drugs. The relative tumor volumes of control (saline) and GOFA-DOX/HACPN groups at day 21 were 2.17 and 1.79 times that at day 0 with no significant difference. In comparison, the relative tumor volumes of treatment groups at the same time were significantly different at 1.02, 0.67 and 0.48 times for DOX, GOFA-DOX and GOFA-DOX/HACPN groups, respectively. The anti-tumor efficacy was also supported by images from an in vivo imaging system (IVIS) using MCF-7 cells transfected with luciferase (MCF-7/Luc). Furthermore, tissue biopsy examination and blood analysis indicated that intratumoral delivery of DOX using GOFA-DOX/HACPN did not elicit acute toxicity. Taken together, GOFA-DOX/HACPN could be deemed as a safe and efficient intratumoral drug delivery system for breast cancer therapy.

Folate Conjugated Trimethyl Chitosan/graphene Oxide Nanocomplexes As Potential Carriers for Drug and Gene Delivery

Chitosan-functionalized Graphene Oxide As a Nanocarrier for Drug and Gene Delivery.

Preparation of folate and carboxymethyl-β-cyclodextrin grafted trimethyl chitosan nanoparticles as co-carrier of doxorubicin and siRNA

Nanodroplets Engineered with Folate Carbon Dots for Enhanced Cancer Cell Uptake toward Theranostic Application

Chitosan-grafted folic acid decorated one-dimensional GONS: A biocompatible drug cargo for targeted co-delivery of anticancer agents

Intratumoral Delivery of Doxorubicin on Folate-Conjugated Graphene Oxide by In-Situ Forming Thermo-Sensitive Hydrogel for Breast Cancer Therapy

Folate Functionalized Mesoporous Carbon Nanospheres As Nanocarrier for Targetted Delivery and Controlled Release of Doxorubicin to HeLa Cells

Self-assembled nanoparticles from folate-decorated maleilated pullulan-doxorubicin conjugate for improved drug delivery to cancer cells

Folic acid modified TPGS as a novel nano-micelle for delivery of nitidine chloride to improve apoptosis induction in Huh7 human hepatocellular carcinoma

Folic acid decorated chitosan nanoparticles and its derivatives for the delivery of drugs and genes to cancer cells

Enhancement of 5-Fluorouracil Drug Delivery in a Graphene Oxide Containing Electrospun Chitosan/Polyvinylpyrrolidone Construct

Preparation and characterization of calcium-doped graphene oxide-chitosan Nanocarrier to enhance the gene delivery in MCF-7 cell line

DNA/chitosan nanocomplex as a novel drug carrier for doxorubicin.

Co-delivery of Doxorubicin and CRISPR/Cas9 or RNAi-expressing Plasmid by Chitosan-Based Nanoparticle for Cancer Therapy.

Pegylated Folate and Peptide-Decorated Graphene Oxide Nanovehicle for in Vivo Targeted Delivery of Anticancer Drugs and Therapeutic Self-Monitoring.

Folate-Mediated And Doxorubicin-Conjugated Poly(Epsilon-Caprolactone)-G-Chondroitin Sulfate Copolymers For Enhanced Intracellular Drug Delivery

Study of folate-based carbon nanotube drug delivery systems targeted to folate receptor α by molecular dynamic simulations

Targeted Minicircle Dna Delivery Using Folate-Poly(Ethylene Glycol)-Polyethylenimine As Non-Viral Carrier

Receptor-mediated Gene Delivery by Folic Acid-Modified Stearic Acid-Grafted Chitosan Micelles.

GFP Plasmid and Chemoreagent Conjugated with Graphene Quantum Dots as a Novel Gene Delivery Platform for Colon Cancer Inhibition In Vitro and In Vivo

Microencapsulated Multifunctionalized Graphene Oxide Equipped with Chloroquine for Efficient and Sustained siRNA Delivery